Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors' reply

Lancet Diabetes Endocrinol. 2024 Apr;12(4):228-229. doi: 10.1016/S2213-8587(24)00063-9.

Authors

Kausik K Ray¹, LeAnne Bloedon², Na Li², Steven E Nissen³; co-authors

Affiliations

¹ Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK. Electronic address: k.ray@imperial.ac.uk.
² Esperion Therapeutics, Ann Arbor, MI, USA.
³ Cleveland Clinic, Cleveland, OH, USA.

PMID: 38514239
DOI: 10.1016/S2213-8587(24)00063-9

No abstract available

Publication types

Letter

MeSH terms

Dicarboxylic Acids
Fatty Acids*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Kidney

Substances

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Fatty Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dicarboxylic Acids